Compare Abbott Laboratories (ABT) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Equinor ASA — how do they compare? Abbott Laboratories trades at $95.31 (market cap $166.94B), while Equinor ASA trades at $34.36 (market cap $77.42B). The key difference: Abbott Laboratories is far larger — about 2.2× Equinor ASA's market cap, and Equinor ASA pays the higher dividend (4.48%). Which is the better fit depends on your goals.
| ABT | EQNR | |
|---|---|---|
Market Cap | $166.94B | $77.42B |
Sector | Health | Energy |
52-Week High | $136.62 | $42.40 |
52-Week Low | $82.57 | $22.41 |
Enterprise Value | $193.69B | $89.19B |
Dividend Yield | 2.63% | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Equinor (EQNR) trades at $33.91, up 5.84% today, with a bearish technical signal despite recent earnings beats. The company shows solid cash flow from operations of $20.0B in 2025 and maintains a low EV/EBITDA of 2.21, but net income has declined to $5.04B. Recent strategic moves include acquiring BP's stake in Bay du Nord and expanding Norwegian gas production, while exiting non-core ventures like Japan offshore wind.
EQNR offers value with low valuation multiples and shareholder returns via dividends and buybacks, but faces risks from volatile energy prices and declining profitability. Analyst sentiment is mixed with 30% buy ratings, reflecting cautious optimism amid execution challenges and macroeconomic pressures on the oil and gas sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
